このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Lyell Immunopharma マネジメント
マネジメント 基準チェック /34
現在、CEO に関する十分な情報がありません。
主要情報
Lynn Seely
最高経営責任者
US$2.6m
報酬総額
| CEO給与比率 | 24.6% |
| CEO在任期間 | 1.6yrs |
| CEOの所有権 | n/a |
| 経営陣の平均在職期間 | 1.9yrs |
| 取締役会の平均在任期間 | 4.3yrs |
経営陣の近況
Recent updates
Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts
Apr 16Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth
Feb 23
Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth
Nov 09Analysts' Revenue Estimates For Lyell Immunopharma, Inc. (NASDAQ:LYEL) Are Surging Higher
Aug 29We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth
Aug 11Lyell Immunopharma (NASDAQ:LYEL) Is In A Good Position To Deliver On Growth Plans
Dec 15Lyell Immunopharma gets FDA nod to start phase 1 trial of its cancer therapy LYL845
Oct 06Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth
Sep 12News Flash: Analysts Just Made A Huge Upgrade To Their Lyell Immunopharma, Inc. (NASDAQ:LYEL) Forecasts
Aug 08Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth
Apr 29We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth
Dec 31Here's Why We're Not Too Worried About Lyell Immunopharma's (NASDAQ:LYEL) Cash Burn Situation
Sep 17CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$228m |
| Dec 31 2023 | US$3m | US$650k | -US$235m |
| Sep 30 2023 | n/a | n/a | -US$190m |
| Jun 30 2023 | n/a | n/a | -US$209m |
| Mar 31 2023 | n/a | n/a | -US$182m |
| Dec 31 2022 | US$19m | US$30k | -US$183m |
| Sep 30 2022 | n/a | n/a | -US$258m |
| Jun 30 2022 | n/a | n/a | -US$237m |
| Mar 31 2022 | n/a | n/a | -US$263m |
| Dec 31 2021 | US$5m | n/a | -US$250m |
報酬と市場: Lynnの 総報酬 ($USD 2.65M ) は、 US市場 ($USD 2.45M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Lynnの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Lynn Seely (65 yo)
1.6yrs
在職期間
US$2,647,476
報酬
Dr. Lynn Seely, MD, Ph D., serves as Lead Independent Director at Blueprint Medicines Corporation since June 2021. She serves as President and Chief Executive Officer at Lyell Immunopharma, Inc. since Dece...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Founder & Executive Chairman | 4.5yrs | US$310.75k | 1.53% $ 5.9m | |
| President | 1.6yrs | US$2.65m | データなし | |
| Chief Financial Officer | 3.4yrs | US$4.32m | 0.0034% $ 13.2k | |
| Chief Operating Officer | 2.7yrs | US$3.11m | 0.0035% $ 13.5k | |
| Chief Scientific Officer | 2.5yrs | US$2.23m | 0.0050% $ 19.2k | |
| Chief Business Officer | less than a year | US$4.26m | データなし | |
| Founder & Scientific Advisor | 1.9yrs | データなし | データなし | |
| Founder & Scientific Advisor | 1.9yrs | データなし | データなし | |
| Director of Accounting | no data | データなし | データなし | |
| Senior Vice President of Communications & Investor Relations | no data | データなし | データなし | |
| Senior Vice President of Human Resources | less than a year | データなし | データなし | |
| Senior Vice President of Clinical Development Operations | less than a year | データなし | データなし |
1.9yrs
平均在職期間
54yo
平均年齢
経験豊富な経営陣: LYELの経営陣は 経験豊富 とはみなされません ( 1.8年の平均在職年数)。これは新しいチームを示唆しています。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Founder & Executive Chairman | 4.5yrs | US$310.75k | 1.53% $ 5.9m | |
| President | 3.2yrs | US$2.65m | データなし | |
| Independent Director | 5.8yrs | US$286.75k | 0% $ 0 | |
| Independent Director | 4.2yrs | US$301.75k | 0% $ 0 | |
| Independent Director | 3.3yrs | US$290.75k | 0% $ 0 | |
| Independent Director | 3.3yrs | US$293.25k | 0% $ 0 | |
| Lead Independent Director | 5.9yrs | US$330.25k | 0.13% $ 507.9k | |
| Independent Director | 5.9yrs | US$285.75k | 1.84% $ 7.1m |
4.3yrs
平均在職期間
64yo
平均年齢
経験豊富なボード: LYELの 取締役会 は 経験豊富 であると考えられます ( 4.3年の平均在任期間)。